文献速递消化系统肿瘤

老年胃癌患者围手术期治疗的依从性、不良事件与生存:TOPGEAR III期试验二次分析

Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial.
PubMed 文献 · Eur J Cancer · 2026-08-22

该研究为AGITG TOPGEAR III期试验的探索性二次分析,纳入574例可切除胃/胃食管结合部腺癌患者,其中135例(24%)≥70岁。老年患者术前化疗减量、遗漏或延迟更常见,≥3级不良事件发生率与年轻患者相当,但血液学毒性和≥3级腹泻更多;切除率、手术并发症及30/90天死亡率相似,OS和PFS在年龄组间可比,老年患者数值上倾向更优。

要点

  • 老年患者术前化疗减量、遗漏或延迟更频繁,但≥3级不良事件总发生率与年轻患者相当。
  • 老年患者化疗组血液学毒性和≥3级腹泻发生率更高。
  • 老年患者手术结局及OS/PFS与年轻患者可比,数值上倾向更优。

核心结论

  • 老年胃癌患者接受围手术期治疗可获得与年轻患者相当的肿瘤学结局,尽管治疗调整更频繁且血液学毒性更高。

研究设计与样本

  • AGITG TOPGEAR III期试验的探索性二次分析,纳入574例可切除胃/胃食管结合部腺癌患者,随机接受单纯围手术期化疗或围手术期化疗联合术前放化疗。

主要发现

  • 574例患者中135例(24%)≥70岁。
  • 老年患者术前化疗减量、遗漏或延迟更常见(放化疗组:55% vs 35%,p=0.004;化疗组:60% vs 48%,p=0.087)。
  • ≥3级不良事件发生率年龄组间相当(放化疗组:66% vs 67%,p=0.874;化疗组:68% vs 59%,p=0.220)。
  • 化疗组老年患者血液学毒性(56% vs 37%,p=0.006)和≥3级腹泻(21% vs 6%,p<0.001)更常见。
  • 切除率、3/4级手术并发症、淋巴结清扫数目及30/90天死亡率年龄组间相似;OS和PFS可比,老年患者数值上更优(OS:HR 0.86,95%CI 0.58-1.26[放化疗];HR 0.75,95%CI 0.51-1.11[化疗];PFS:HR 0.78,95%CI 0.53-1.15[放化疗];HR 0.70,95%CI 0.47-1.03[化疗])。

临床怎么用

  • 老年胃癌患者可考虑围手术期化疗或化疗联合术前放化疗,但需密切监测血液学毒性和腹泻,并预期更频繁的剂量调整。

局限性

  • 该分析为探索性二次分析,老年患者样本量有限(135例),统计效能可能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate treatment adherence, adverse events, and survival in older (≥70 years) adults undergoing perioperative treatment for gastric cancer. METHODS: Patients with resectable gastric/gastro-esophageal junction adenocarcinoma (ECOG 0-1) enrolled in the phase III TOPGEAR trial were randomized to perioperative chemotherapy (ECF/ECX or FLOT) alone or perioperative chemotherapy plus preoperative chemoradiotherapy (45 Gy in 25 fractions with concurrent fluoropyrimidine). In this exploratory analysis, treatment completion, grade ≥ 3 adverse events (CTCAE v3.0), surgical outcomes, overall survival (OS) and progression-free survival (PFS) were compared between older and younger adults. RESULTS: Of the 574 patients enrolled, 135 (24%) were ≥ 70 years. Older adults more frequently required preoperative chemotherapy dose reductions, omissions, or delays (chemoradiotherapy: 55% vs 35%, p = 0.004; chemotherapy: 60% vs 48%, p = 0.087). Rates of grade ≥ 3 adverse events were comparable between older and younger patients (chemoradiotherapy: 66% vs 67%, p = 0.874; chemotherapy: 68% vs 59%, p = 0.220), but older adults more often had hematologic toxicity and grade ≥ 3 diarrhea in the chemotherapy group (56% vs 37%, p = 0.006; 21% vs 6%, p < 0.001). Resection rates, grade 3/4 surgical complications, number of removed lymph nodes, and 30-/90-day mortality were similar by age. OS and PFS were comparable across age groups, with numerically favorable outcomes for older adults (OS: HR 0.86, 95% CI 0.58-1.26 [chemoradiotherapy]; HR 0.75, 95% CI 0.51-1.11 [chemotherapy]; PFS: HR 0.78, 95% CI 0.53-1.15 [chemoradiotherapy]; HR 0.70, 95% CI 0.47-1.03 [chemotherapy]). CONCLUSIONS: Older adults with gastric cancer achieved comparable oncologic outcomes to younger patients, despite more frequent treatment modifications and higher hematologic toxicity.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rühle A, Krause A, O'Connell RL, et al. Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial. Eur J Cancer. 2026. PMID: 42673704. doi:10.1016/j.ejca.2026.117005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。